Every 8-K that Bristol-Myers Squibb Co. (BMY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMY filings page.
Bristol Myers Squibb Company reported second-quarter 2026 results with total revenue of $12,973 million, up 6% year over year. The Growth Portfolio generated $7,560 million, up 15%, while the Legacy Portfolio was $5,422 million, down 4% as generic erosion offset Eliquis growth.
GAAP diluted EPS rose to $1.62 from $0.64, and non-GAAP diluted EPS increased to $2.04 from $1.46. Eliquis revenue grew 22% to $4,481 million, while Revlimid and Pomalyst declined sharply. Net income attributable to Bristol Myers Squibb was $3,317 million.
The company raised its 2026 non-GAAP revenue outlook to $49.0–$50.0 billion and increased non-GAAP EPS guidance to $6.75–$7.00, reflecting broad portfolio momentum and higher Eliquis expectations. Guidance assumes 20–25% worldwide Eliquis revenue growth and operating expenses of about $16.5 billion.
Bristol-Myers Squibb Company reported voting results from its annual shareholder meeting. Shareholders elected all 11 director nominees to serve until the 2027 annual meeting, with each receiving over 1.46 billion votes in favor and substantial broker non-votes recorded.
Shareholders approved, on an advisory basis, the compensation of named executive officers with 1,459,162,310 votes for and 72,490,026 against, and also approved the Company’s 2026 stock award and incentive plan with 1,470,672,957 votes for and 63,896,918 against. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified. A shareholder proposal to require the board chairperson to be an independent director did not pass, receiving 422,069,323 votes for and 1,109,378,680 votes against.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, up 3% year over year (1% Ex-FX). The Growth Portfolio generated $6.2 billion, rising 12% (9% Ex-FX), while the Legacy Portfolio declined to $5.3 billion, down 6%.
Key products included Eliquis with $4.1 billion in worldwide sales, up 16%, and strong growth from newer brands such as Camzyos, Breyanzi, Reblozyl and Opdualag. U.S. revenue was $7.8 billion, down 1%, and international revenue was $3.7 billion, up 11% (4% Ex-FX).
GAAP diluted EPS increased to $1.31 from $1.20, while non-GAAP EPS decreased to $1.58 from $1.80, reflecting higher research and development spending and lower other income. Net income attributable to the company was $2.7 billion on a GAAP basis and $3.2 billion on a non-GAAP basis.
The company reaffirmed its 2026 non-GAAP guidance, including total revenue of ~$46.0–$47.5 billion and non-GAAP diluted EPS of $6.05–$6.35, with both revenue and EPS expected to trend toward the upper end of these ranges.
Bristol-Myers Squibb Company furnished an update on its recent performance by issuing an earnings press release and investor presentation covering financial results for the fourth quarter of 2025 and the full year 2025.
The company posted the earnings press release and a “Bristol Myers Presentation” on its website in connection with an earnings conference call and webcast. Both materials include non-GAAP financial measures, with reconciliations and explanations provided in the press release. These materials are furnished, not filed, under the Exchange Act and are not automatically incorporated into future SEC filings.
Bristol-Myers Squibb Company reported that it has made a new investor presentation available on its website as of January 12, 2026. The company furnished this presentation as Exhibit 99.1 to a current report, giving investors another source of information about its business and outlook. The report explains that this information is being furnished under disclosure rules and is not considered filed for liability purposes or automatically incorporated into other regulatory documents.
Bristol Myers Squibb Company reported that it has announced early participation results, an amendment and early settlement for previously launched cash tender offers to purchase its outstanding notes. The company also disclosed the accepted amounts and pricing terms for these tender offers in a subsequent press release. These actions are governed by an Offer to Purchase dated November 3, 2025, which sets out the detailed terms and conditions and limits where the offers are valid.
Bristol Myers Squibb, through BMS Ireland Capital Funding DAC, completed a euro‑denominated senior notes offering guaranteed by the company. The issuance includes €750,000,000 of 2.973% notes due 2030, €1,150,000,000 of 3.363% notes due 2033, €1,150,000,000 of 3.857% notes due 2038, €750,000,000 of 4.289% notes due 2045, and €1,200,000,000 of 4.581% notes due 2055. Interest is payable each November 10, beginning in 2026, with make‑whole call spreads of +10 to +20 bps by tranche, and the issuer may redeem the notes at its option on stated terms.
The company intends to use the net proceeds, together with approximately $3.0 billion of cash on hand, to fund a cash tender offer for various outstanding Bristol Myers Squibb notes and/or other repurchase, repayment or redemption of those notes, pay related fees and expenses, and, to the extent of any remainder, for general corporate purposes.
Bristol Myers Squibb announced the commencement of cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum and Pool 2 Maximum.
The offers are being made only pursuant to the Company’s Offer to Purchase dated November 3, 2025, which sets forth the detailed terms and conditions. A related press release is furnished as Exhibit 99.1.
Bristol-Myers Squibb (BMY) furnished materials related to its third-quarter 2025 results. The company posted an earnings press release and an investor presentation on its website, and furnished them as Exhibits 99.1 and 99.2. The materials reference non-GAAP metrics, with reconciliations included in the press release.
The presentation supported the company’s Q3 2025 conference call and webcast at 8:00 a.m. Eastern time. Information furnished under Item 7.01, including Exhibits 99.1 and 99.2, is not deemed filed under the Exchange Act.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act §18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities—common stock, 1.750 % notes due 2035, and Celgene CVRs—and contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K – Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.